TY - JOUR
T1 - Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE)
T2 - A randomised, phase 3, double-blind study
AU - Calabresi, Peter A.
AU - Kieseier, Bernd C.
AU - Arnold, Douglas L.
AU - Balcer, Laura J.
AU - Boyko, Alexey
AU - Pelletier, Jean
AU - Liu, Shifang
AU - Zhu, Ying
AU - Seddighzadeh, Ali
AU - Hung, Serena
AU - Deykin, Aaron
N1 - Funding Information:
PAC has received grants and research support from Biogen Idec, Abbott, Vertex, Novartis, and Bayer, and consulting fees from Abbott, Vaccinex, and Vertex. BCK has received grants and research support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Talecris, and Teva Neurosciences, and consulting fees from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Talecris, and Teva Neurosciences. DLA has received grant and research support from Bayer Healthcare and consulting fees from Bayer Healthcare, Biogen Idec, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, NeuroRx Research, Novartis, Roche, Merck Serono, and Teva. LJB has received consulting fees from Biogen Idec, Questcor, and Novartis. AB has received consulting fees from Schering, Merck Serono, Teva, Novartis, Biogen Idec, Nycomed, and Genzyme. JP has received consulting fees from Allergan, Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi, and Teva; non-profit foundation support from ARSEP; academic research support from PHRC; and unconditional research support from Bayer Schering Pharma, Biogen Idec, BristolMyers-Squibb, GlaxoSmithKline, Merck Serono, Novartis, Peptimmune, Roche, Sanofi, Teva, and Wyeth. SL, YZ, AS, SH and AD are employees of Biogen Idec.
PY - 2014/7
Y1 - 2014/7
N2 - Background: Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Methods: We did this 2-year, double-blind, parallel group, phase 3 study, with a placebo-controlled design for the first 48 weeks, at 183 sites in 26 countries. Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks. The primary endpoint was annualised relapse rate at 48 weeks. This trial is registered with ClinicalTrials.gov, number NCT00906399. Findings: We screened 1936 patients and enrolled 1516, of whom 1512 were randomly assigned (500 to placebo, 512 to peginterferon every 2 weeks, 500 to peginterferon every 4 weeks); 1332 (88%) patients completed 48 weeks of treatment. Adjusted annualised relapse rates were 0·397 (95% CI 0·328-0·481) in the placebo group versus 0·256 (0·206-0·318) in the every 2 weeks group and 0·288 (0·234-0·355) in the every 4 weeks group (rate ratio for every 2 weeks group 0·644, 95% CI 0·500-0·831, p=0·0007; rate ratio for the every 4 weeks group 0·725, 95% CI 0·565-0·930, p=0·0114). 417 (83%) patients taking placebo, 481 (94%) patients taking peginterferon every 2 weeks, and 472 (94%) patients taking peginterferon every 4 weeks reported adverse events including relapses. The most common adverse events associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrexia, and headache. 76 (15%) patients taking placebo, 55 (11%) patients taking study drug every 2 weeks, and 71 (14%) patients taking study drug every 4 weeks reported serious adverse events; relapse, pneumonia, and urinary tract infection were the most common. Interpretation: After 48 weeks, peginterferon beta-1a significantly reduced relapse rate compared with placebo. The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequent administration than available treatments. Funding: Biogen Idec.
AB - Background: Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. Methods: We did this 2-year, double-blind, parallel group, phase 3 study, with a placebo-controlled design for the first 48 weeks, at 183 sites in 26 countries. Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks. The primary endpoint was annualised relapse rate at 48 weeks. This trial is registered with ClinicalTrials.gov, number NCT00906399. Findings: We screened 1936 patients and enrolled 1516, of whom 1512 were randomly assigned (500 to placebo, 512 to peginterferon every 2 weeks, 500 to peginterferon every 4 weeks); 1332 (88%) patients completed 48 weeks of treatment. Adjusted annualised relapse rates were 0·397 (95% CI 0·328-0·481) in the placebo group versus 0·256 (0·206-0·318) in the every 2 weeks group and 0·288 (0·234-0·355) in the every 4 weeks group (rate ratio for every 2 weeks group 0·644, 95% CI 0·500-0·831, p=0·0007; rate ratio for the every 4 weeks group 0·725, 95% CI 0·565-0·930, p=0·0114). 417 (83%) patients taking placebo, 481 (94%) patients taking peginterferon every 2 weeks, and 472 (94%) patients taking peginterferon every 4 weeks reported adverse events including relapses. The most common adverse events associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrexia, and headache. 76 (15%) patients taking placebo, 55 (11%) patients taking study drug every 2 weeks, and 71 (14%) patients taking study drug every 4 weeks reported serious adverse events; relapse, pneumonia, and urinary tract infection were the most common. Interpretation: After 48 weeks, peginterferon beta-1a significantly reduced relapse rate compared with placebo. The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequent administration than available treatments. Funding: Biogen Idec.
UR - http://www.scopus.com/inward/record.url?scp=84902544766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902544766&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(14)70068-7
DO - 10.1016/S1474-4422(14)70068-7
M3 - Article
C2 - 24794721
AN - SCOPUS:84902544766
SN - 1474-4422
VL - 13
SP - 657
EP - 665
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 7
ER -